Given the evidence available at this time, treatment with axicabtagene ciloleucel appears to be associated with positive but uncertain gains in survival compared with chemotherapy over a lifetime horizon. Under certain long-term survival assumptions, treatment with axicabtagene ciloleucel also appears to be cost-effective. Data from patients receiving this novel CAR-T therapy should continue to be collected to reduce the uncertainty in long-term survival and thus cost-effectiveness estimates.
